A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs

🅇

Currently Recruiting

This trial is actively seeking participants in the UK. Discuss eligibility with your patient.

Status

Recruiting

Phase

N/A

NCT ID

NCT05663515

Trial Summary

EXCEED is a non-interventional post-authorisation safety study aiming to assess the risk of developing pancreatic cancer among type 2 diabetes mellitus (T2DM) patients who initiated exenatide compared to those who initiated other non-glucagon like peptide 1 receptor agonists (GLP-1 RA) based glucose lowering drugs (GLDs). Study data will be collected from secondary data sources across 7 European countries. The study will be conducted as a multi-country, long-term, retrospective, observational database study. Initiators of exenatide will be matched to initiators of non-GLP-1 RA based GLDs (comparator group) based on propensity score and calendar period of study entry. All analyses for pancreatic cancer will be conducted in the matched study population using an "intention-to-treat" approach. The study will use information from 8 data sources in 7 European countries (France, Spain, The United Kingdom, Finland, Denmark, Norway, and Sweden). Patients with T2DM, aged 18 years or older, who initiated treatment with exenatide or non-GLP-1 RA based GLDs during the study period, 2006 to 2023, will be included. Exposure to exenatide and non-GLP-1 RA based GLDs will be ascertained from recordings of prescriptions or insurance claims registrations as available in the different data sources. The outcome of pancreatic cancer will be defined as a primary diagnosis of pancreatic cancer during follow-up.

Lead Sponsor: AstraZeneca

Participants: ALL

Start Date: 2024-09-30

Primary Completion: 2026-10-01

Min Age: 18 Years

Max Age: 99 Years

Eligibility Criteria

For inclusion in either exposure group, all of the following inclusion criteria must be fulfilled: 1. Aged 18 years or older at the index date 2. Individual level data on prescriptions, diagnoses and medical history is available for a minimum of 12 months prior to the index date 3. A diagnosis of T2DM on index date or prior to index date For inclusion in the overall exenatide exposure group, the following criterion must be fulfilled: 1. One incident prescription (or incident dispensed prescription) for exenatide (BYETTA or BYDUREON/ BYDUREON BCise) between the start and 12 months before the end of the study period. This incident prescription must have succeeded a prescription of a GLD of another drug class during the baseline period. For inclusion in the BYDUREON/ BYDUREON BCise exposure group, for the analyses of the secondary objective, the criterion a) is substituted with criterion b): 2. One incident prescription (or incident dispensed prescription) for BYDUREON/ BYDUREON BCise between the start and 12 months before the end of the study period. This incident prescription must have succeeded a prescription of a GLD of another drug class during the baseline period. For inclusion in the comparator group, the following criterion must…

View Full Trial on ClinicalTrials.gov ↗

Data sourced from ClinicalTrials.gov. Trial details may change — always check the primary source before clinical decisions.

Share: 𝕏 Twitter/X 🔗 LinkedIn View on Source ↗